Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Unum Therapeutics Inc (UMRX)

Unum Therapeutics Inc (UMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Unum Therapeutics Inc 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 USA

www.unumrx.com P: 617-945-5576

Description:

Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 99,802
Shares Outstanding, K 42,469
Annual Sales, $ 22,500 K
Annual Net Income, $ -31,830 K
Last Quarter Sales, $ 530 K
Last Quarter Net Income, $ -7,390 K
60-Month Beta 3.97
% of Insider Shareholders 31.50%
% of Institutional Shareholders 26.39%
Float, K 29,091
% Float 68.50%

Growth:

1-Year Return 59.86%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/10/20
Earnings Per Share ttm -0.76
EPS Growth vs. Prev Qtr -20.00%
EPS Growth vs. Prev Year 29.41%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

UMRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -87.78%
Return-on-Assets % -52.14%
Profit Margin % -141.47%
Debt/Equity 0.00
Price/Sales 4.42
Price/Cash Flow N/A
Price/Book 3.81
Book Value/Share 0.62
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar